Vazyme, China's leading biotechnology company, has officially signed a global strategic cooperation agreement with US-based Azenta Life Sciences, which will promote to establish "one-stop" service process for both companies in the fields of next-generation sequencing, automated library preparation, raw material supply, experimental consumables, sample storage and more.

Vazyme reported strong financial performance in 2022. The company's operating revenue reached $517.25 million, a 90.99 percent growth year-on-year, and its regular business revenue of $146.96 million increased by 41.03 percent year-on-year. Life science, in vitro diagnostics, and bio-medicine were business sectors with top three growth and performance.

To meet the varying needs of  customers and partners, Vazyme invested a total of $57.39 million in R&D in 2022, which was a 71.98 percent increase year-on-year, and its R&D team now has 1,196 researchers. By the end of 2022, Vazyme has obtained 109 patents, including 53 patents for invention, and it has built state-of-the-art R&D and production facilities that will meet various product needs.

Looking forward, Vazyme and Azenta will carry out global cooperation in the fields of automated sample solutions, oligo synthesis, molecular biology services, and GLP standard specification services, fully integrating the resources and advantages of both companies to lead innovative breakthroughs, jointly developing international markets, and contributing to the life and health of all people.